8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 11, 2017

The Spectranetics Corporation

(Exact name of registrant as specified in its charter)

Delaware	000-19711	84-0997049
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

9965 Federal Drive

Colorado Springs, Colorado 80921

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (719) 633-8333

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 11, 2017, The Spectranetics Corporation (the “Company”) announced that Scott Hutton has accepted an appointment as General Manager, Vascular Intervention, effective on January 23, 2017. In this role, Mr. Hutton will report directly to Scott Drake, President and Chief Executive Officer. The Company’s appointment of Mr. Hutton was announced in a press release, dated January 11, 2017, which is attached to this Form 8-K as Exhibit 99.1.

Mr. Hutton, age 45, most recently served as Vice President and General Manager of the Neurosurgery Business Unit of Medtronic plc, a global medical technology, services and solutions company, from April 2012 to the present. In this role, he oversaw the operations of the approximately $1 billion Neurosurgery Business Unit. Prior to joining the Neurosurgery Business Unit, he served in Medtronic’s Navigation Business Unit as Vice President and Business Leader from July 2011 to April 2012 and as Senior Director, Global Marketing from December 2008 to July 2011. Mr. Hutton also held a number of marketing and business development roles of increasing responsibility within Medtronic’s Spinal & Biologics Division from December 2000 until December 2008.

In connection with his appointment, Mr. Hutton will receive an annual base salary of $350,000 and will be eligible to receive a pro-rated cash bonus under the Company’s annual short-term performance-based cash incentive award program for 2017 with a target incentive opportunity of 50% of his pro-rated 2017 base salary. Mr. Hutton will receive a cash sign-on bonus of $140,000; a stock option grant valued at approximately $100,000 that will vest over four years; a restricted stock unit grant valued at approximately $400,000 that will vest over four years; and a performance stock unit grant valued at approximately $200,000 that will vest on December 31, 2019, based on established performance metrics and terms that are consistent with awards granted to the Company’s other executive officers in 2017. He will participate on the same basis as the Company’s other executive officers in the Company’s annual short-term performance-based cash incentive award program and long-term equity incentive program, and it is expected that Mr. Hutton will enter into a severance and change in control agreement with the Company after six months of employment with the Company. These plans and agreements are described in more detail under the heading “Compensation Discussion and Analysis” in the Company’s proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2016. Mr. Hutton also will be entitled to participate in the Company’s health and other benefit plans generally available to the Company’s executive officers. Mr. Hutton will be an “at-will” employee of the Company and will have no specified term as General Manager, Vascular Intervention. There are no related person transactions between Mr. Hutton and the Company.

ITEM 9.01         Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated January 11, 2017, issued by The Spectranetics Corporation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		THE SPECTRANETICS CORPORATION
Date:	January 11, 2017	By:	/s/ Paul Gardon
			Paul Gardon
			Senior Vice President, General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated January 11, 2017, issued by The Spectranetics Corporation.

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Spectranetics Names Scott Hutton as General Manager, Vascular Intervention

COLORADO SPRINGS, COLO. (January 11, 2017) - The Spectranetics Corporation (NASDAQ: SPNC), (“the Company”) today announced that Scott Hutton has been named General Manager, Vascular Intervention, effective January 23^rd, 2017. In this role, Mr. Hutton will report directly to Scott Drake, President and Chief Executive Officer.

Mr. Hutton brings a wealth of industry experience and leadership to Spectranetics. He spent the last 16 years with Medtronic, most recently leading the Neurosurgery business unit as the Vice President and General Manager. Prior to joining the Neurosurgery business, Scott led Medtronic Navigation, the world’s leading provider of integrated navigation and intra-operative imaging solutions. He also held numerous global marketing and business development roles of increasing responsibility during his tenure at Medtronic.

"We are pleased to name industry veteran Scott Hutton as the leader of our Vascular Intervention franchise," said Scott Drake, President and CEO. "Scott’s track record of creating value makes him the ideal candidate to capitalize on our many opportunities and lead the Vascular Intervention business through its next phase of growth. We are excited to unite his world class expertise with our team to further improve the lives of our patients.”

Mr. Hutton stated, "I'm excited for the opportunity to play such a vital role in helping Spectranetics achieve its next stage of growth. The Vascular Intervention franchise is an attractive business with compelling growth opportunities that will be integral to the future success of the Company. I’m also proud to be joining Spectranetics’ commitment to leading the way in clinical science in order to provide physicians and patients with proven treatment algorithms and advancements in therapy options.”

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “look forward,” “strive,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “enable,” “potential,” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, clinical trials and regulatory approvals, regulatory or competitive environments, outcome of litigation, our intellectual property and product development. These forward-looking statements include, but are not limited to, statements regarding our competitive position, product development and commercialization schedule, expectation of continued growth and the reasons for that growth, growth rates, strength, integration and product launches, and 2016 and 2017 outlook and projected results including projected revenue and expenses, net loss and gross margin. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements and to note they speak only as of the date of this release. These risks and uncertainties may include financial results differing from guidance, inability to successfully integrate AngioScore and Stellarex into our business, market acceptance of excimer laser atherectomy technology and our vascular intervention and lead management products, lack of cash necessary to satisfy our cash obligations under our outstanding 2.625% Convertible Senior Notes due 2034 and our term loan and revolving loan facilities, our debt adversely affecting our financial health and preventing us from fulfilling our debt service and other obligations, increasing price and product competition, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of our strategic direction, dependence on new product development, loss of key personnel, uncertain success of or delays in our clinical trials, costs of and adverse results in any ongoing legal proceeding, or any legal proceeding in which we may become involved, adverse impact to our business of the health care reform and related legislation or regulations, including changes in reimbursements, continued or worsening adverse conditions in the general domestic and global economic markets and continued volatility and disruption of the credit markets, which affects the ability of hospitals and other health care systems to obtain credit and may impede our access to capital, intellectual property claims of third parties, availability of inventory from suppliers, adverse outcome of FDA inspections, the receipt of FDA

clearance and other regulatory approvals to market new products or applications and the timeliness of any clearance and approvals, market acceptance of new products or applications, product defects, ability to manufacture sufficient volumes to fulfill customer demand, availability of vendor-sourced components at reasonable prices, unexpected delays or costs associated with any planned improvements to our manufacturing processes, and share price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause our actual results, performance or achievements to materially differ from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those risks set forth in our 2015 Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

Investor Relations Contacts

Zach Stassen

Investor.relations@spnc.com

(719) 447-2292

Michaella Gallina

Investor.relations@spnc.com

(719) 246-1713